Zymeworks (ZYME) Liabilities and Shareholders Equity (2021 - 2026)

Zymeworks has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $478.2 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $478.2 million, up 12.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 13.8% YoY), and the FY2025 annual result was $346.5 million, down 25.17% from the prior year.
• Liabilities and Shareholders Equity came in at $478.2 million for Q1 2026 at Zymeworks, up from $346.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $648.7 million in Q4 2022 to a low of $300.3 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $487.2 million (2024), against an average of $491.0 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 85.29% in 2023 and decreased 25.17% in 2025, its largest moves.
• Zymeworks' Liabilities and Shareholders Equity stood at $648.7 million in 2022, then declined by 10.46% to $580.9 million in 2023, then declined by 20.28% to $463.1 million in 2024, then fell by 25.17% to $346.5 million in 2025, then surged by 38.0% to $478.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $478.2 million (Q1 2026), $346.5 million (Q4 2025), and $397.3 million (Q3 2025), per Business Quant data.